Graham Capital Management’s Inhibrx INBX Stock Holding History

Graham Capital Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,242	Closed	-$352K	–	1370
2026 Q1	$352K	Buy	+5,242	New	+$389K	0.01%	752

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Graham Capital Management's INBX Position: Q2 2026 in Review

Graham Capital Management sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 5,242 shares — an estimated $352K sold.

Graham Capital Management first reported a position in INBX in Q1 2026 and held it in 1 quarter. The position peaked at $352K in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Graham Capital Management reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 5,242 Inhibrx shares in Q2 2026, an estimated $352K.
Graham Capital Management first reported a position in Inhibrx in Q1 2026 and held it in 1 quarter.
Graham Capital Management's Inhibrx position peaked at $352K in Q1 2026.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.